Probiomics (PCC)

Shares / Stock Code


Stock Exchange / Sharemarket


Probiomics (PCC) is a specialist biotechnology company focused on the development of products incorporating PCC®, a strain of Lactic Acid Bacteria (probiotic). Its probiotic products include Progastrim®, sold exclusively to naturopaths, and proTract®, a family of products for intestinal health, diarrhoea and irritable bowel syndrome and for atopic dermatitis. Both these products are listed on the Australian Register of Therapeutic Goods.

Probiomics (formerly VRI BioMedical) was incorporated in 1997 and listed on the Australian stockmarket (ASX) ASX in December 2000 to fund the R&D of a portfolio of projects in mucosal immunology. Its first commercialisation agreement was with US-based Pharmanex. ProBioPCC, a probiotic-based dietary supplement, contained PCC's strain of Lactobacillus fermentum, sold by Pharmanex to North America and Asian countries. PCC changed its name in April 2005 to reflect the primary focus on probiotics and associated molecules.

PCC's probiotic products address significant markets. The Wellness Industry, those of the ageing population seeking products to maintain health and well-being. PCC® maintains intestinal health by inhibiting harmful micro-organisms, restoring a balance of bacteria and boosting the immune system. In addition, PCC® relieves symptoms of gastrointestinal disorders triggered by underlying pathogenic organisms.

Major customers of this Australian sharemarket listed company in relation to its Progastrim® and proTract® product range are mainly pharmacies and health specialists, locally and internationally. Competitors include other research institutes and companies producing generic products.

Probiomics (PCC) Products and Services

  • Biotechnology.

Probiomics (PCC) Locations and Subsidiaries

Probiomics Head Office
Suite 1A, Level 2, 802 Pacific Highway,
Phone: (02) 9844 5422
Fax: (02) 9844 5445

Probiomics (PCC) Share Price

Submitted by ASX Listed Company on 20 May, 2010 - 17:56